The Efficacy of Fycompa (Perampanel) in Children With Epilepsy
Status
Conditions
Treatments
Details and patient eligibility
About
Fycompa (Perampanel), a new anti-epileptic drug that uses a new mechanism-AMPA receptor antagonist. Its initial indication is for local or generalized epilepsy in children and adults over 12 years old, but its effectiveness in the treatment of epilepsy in children At present, more evidence is still needed. We will study the effectiveness of Fycompa (Perampanel) in the treatment of epilepsy in children under the age of 18. It is expected that the clinical use of Fycompa (Parampanel) in Taiwan will be able to analyze and study the effectiveness of the clinical use of Fycompa (Parampanel) in the treatment of epilepsy in children, and compare it with foreign reports.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- Patients under 18 years of age suffering from epilepsy
- Patients who are taking Paraampanel
Exclusion criteria
- Patients who are not in the above age groups and who are not using parampanel
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal